Close

BIO Statement on Hatch-Waxman Integrity Act of 2019

BIO applauds the leadership of Senator Thom Tillis (R- NC) and Congressman Bill Flores (R-17 TX) for introducing the “Hatch-Waxman Integrity Act of 2019” to preserve the time-tested approach of the HWA while strengthening the ability of patent owners to fairly defend against abusive efforts to invalidate patents for innovative life-saving medical therapies.

BIO's Comment on Advanced Notice of Proposed Rulemaking Regarding Review of Controls for Certain Emerging Technologies

BIO urges the Administration to fully assess the potential impact of export controls on biotechnologies on “the impact on the economy of the United States” and on the sustainability of the U.S....

BIO’s Jim Greenwood Meets with India’s PM Modi

Delivers Message: India Must Protects Innovators’ Work Product

New York U.S. Congressional Delegation Sends Letter to PTO Head Michelle Lee

Ten members the U.S. House of Representatives from New York wrote to U.S. Patent and Trademark Office Director Michelle K. Lee to express concern with continued abuse of the inter partes review (IPR) system by financial speculators and other third parties with no legitimate interests in the patented technology

BIO Position on Proposals to Provide for Export Manufacturing Exemption during Patent Term Restoration

Export manufacturing exemptions weaken the IP protections afforded by Supplementary Protection Certificate and Patent Term Restoration.

Neat, Plausible, and Wrong

Why the focus on intellectual property fails to address the complexities of medicinal access in India Stephen M. Sammut and Daniel S. Levine Released in San Francisco, June, 2016 Supported by and prepared for the Biotechnology Innovation Organization and the Association of Biotechnology Led Enterprises The opinions expressed in this paper are those of the authors and do not necessarily reflect the opinions of BIO and ABLE.

BIO Statement Regarding the UN High Level Panel on Access to Medicines Report

Sadly the United Nations High Level Panel ignored the real issues that impact or delay delivery of innovative treatments and cures throughout the developing world, while focusing on policy recommendations in the one area – intellectual property – that would actually undermine ongoing research and development by hundreds of companies, universities and researchers.  

Ted Roumel, Vice President for Research Innovation & Commercialization at the University of Maryland Biotechnology Institute, USA

Innovation And The Global Research Enterprise WORLD HEALTH ORGANIZATION GENEVA—NOVEMBER 2007 THEODORE J. ROUMEL VICE PRESIDENT for RESEARCH, INNOVATION AND COMMERCIALIZATION UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE

Diran Makinde, Network Director, NEPAD Biosciences, West Africa Biosciences Network (WABNet), Senegal

Government's role in developing solutions for diseases that disproportionately affect developing countries

Presentation: "Global Health Challenges: How Industry is Addressing Global Health", presented at the University of Virginia in June 2008

Global Health Challenges: How Industry is Addressing Global Health